Market Cap 3.77B
Revenue (ttm) 560.23M
Net Income (ttm) -569.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.60%
Debt to Equity Ratio 0.00
Volume 1,101,800
Avg Vol 1,044,326
Day's Range N/A - N/A
Shares Out 94.54M
Stochastic %K 92%
Beta 0.26
Analysts Strong Sell
Price Target $89.89

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
OutperformGER
OutperformGER Jul. 5 at 5:42 AM
$MREO and $RARE This should have a big positive impact https://www.wsj.com/opinion/orphan-drugs-gop-budget-bill-price-controls-inflation-reduction-act-19520a0d?st=28o28L
1 · Reply
javarich
javarich Jul. 4 at 11:53 AM
$BBIO $HLXB $RARE $MREO $BBOT Working to hard this morning. If you’re in here then you need to be in the spac spinoff o $BBOT this is the oncology division. https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html BridgeBio Oncology Therapeutics (BBOT) is directly connected to BridgeBio Pharma (BBIO) and Helix Acquisition Corp. II (HLXB). Here’s how they’re linked: Buy Helix now or don’t we get the worm late birds. The team is just too good to fail. 10x is all we do… ✅ Bottom Line • BridgeBio Pharma launched BBOT as part of its “hub-and-spoke” model to focus and accelerate oncology innovation. • Helix Acquisition Corp. II (HLXB) serves as the SPAC vehicle to take BBOT public, merging in Q3 2025 under the BBOT ticker. • Post-transaction, BBOT will be well-funded with ~$550M to advance its RAS/PI3K-targeted oncology programs.
0 · Reply
CrispDry
CrispDry Jul. 2 at 10:27 PM
$RARE feels like we are very close. Volatility increasing $MREO
0 · Reply
javarich
javarich Jul. 2 at 3:38 PM
$RARE $MREO I'm in this shit is too easy and really not even sure why I care to share. Maybe its my love at the molecular level. Also this guy at $KAPA MIT I went to UNLV $CRCL The hate you have going to eat you up at the cellular level ask $AAPL CEO
0 · Reply
javarich
javarich Jul. 2 at 2:54 PM
$SLS I'm in if you care these are the Pharma #lgcyholo $RARE $KAPA look up pipe, team and look into your soul I bought Lambos years ago now I'm a buddist beetchs
0 · Reply
javarich
javarich Jul. 2 at 2:49 PM
$BBAI so glad I CA down to under $4 this is the next $PLTR kinda sorta. Best Pharma plays on the plant $RARE $KAPA
2 · Reply
javarich
javarich Jul. 2 at 2:47 PM
$RARE $KAPA I reallt should be charging for this but I love when others win too. Be a early bird not late
0 · Reply
CrispDry
CrispDry Jul. 2 at 3:15 AM
$RARE when’s the data coming :/
1 · Reply
javarich
javarich Jul. 1 at 4:27 PM
$RARE tired of the chick spitting in her coffee gtfo is your not in. Analysts azzwipe. 3x mark it, post it, pin it to your cinder in basement.
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 4:27 PM
$RARE secures FDA Breakthrough Therapy status for GTX-102! This designation could accelerate the development and review of treatment for Angelman syndrome, supported by promising early clinical data showing sustained improvements in patients. With shares down 13.2% YTD and limited existing treatments, this could be a pivotal moment for Ultragenyx Pharmaceuticals. Discover the full story here 👉 https://www.zacks.com/commentary/2557986/rares-gtx-102-gets-fdas-breakthrough-status-for-angelman-syndrome?cid=sm-stocktwits-2-2557986-body-455&ADID=SYND_STOCKTWITS_TWEET_2_2557986_BODY_455
0 · Reply
Latest News on RARE
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline

Apr 16, 2025, 9:49 AM EDT - 2 months ago

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline


Ultragenyx to Participate at Investor Conferences in March

Feb 24, 2025, 4:30 PM EST - 4 months ago

Ultragenyx to Participate at Investor Conferences in March


Ultragenyx to Participate in Investor Conferences in December

Nov 26, 2024, 4:30 PM EST - 7 months ago

Ultragenyx to Participate in Investor Conferences in December


Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12, 2024, 11:12 AM EST - 8 months ago

Ultragenyx: Ready For More Growth After Q3 Earnings Beat


Ultragenyx to Participate in Investor Conferences in September

Aug 29, 2024, 4:30 PM EDT - 11 months ago

Ultragenyx to Participate in Investor Conferences in September


OutperformGER
OutperformGER Jul. 5 at 5:42 AM
$MREO and $RARE This should have a big positive impact https://www.wsj.com/opinion/orphan-drugs-gop-budget-bill-price-controls-inflation-reduction-act-19520a0d?st=28o28L
1 · Reply
javarich
javarich Jul. 4 at 11:53 AM
$BBIO $HLXB $RARE $MREO $BBOT Working to hard this morning. If you’re in here then you need to be in the spac spinoff o $BBOT this is the oncology division. https://finance.yahoo.com/news/bridgebio-oncology-therapeutics-bbot-helix-124900685.html BridgeBio Oncology Therapeutics (BBOT) is directly connected to BridgeBio Pharma (BBIO) and Helix Acquisition Corp. II (HLXB). Here’s how they’re linked: Buy Helix now or don’t we get the worm late birds. The team is just too good to fail. 10x is all we do… ✅ Bottom Line • BridgeBio Pharma launched BBOT as part of its “hub-and-spoke” model to focus and accelerate oncology innovation. • Helix Acquisition Corp. II (HLXB) serves as the SPAC vehicle to take BBOT public, merging in Q3 2025 under the BBOT ticker. • Post-transaction, BBOT will be well-funded with ~$550M to advance its RAS/PI3K-targeted oncology programs.
0 · Reply
CrispDry
CrispDry Jul. 2 at 10:27 PM
$RARE feels like we are very close. Volatility increasing $MREO
0 · Reply
javarich
javarich Jul. 2 at 3:38 PM
$RARE $MREO I'm in this shit is too easy and really not even sure why I care to share. Maybe its my love at the molecular level. Also this guy at $KAPA MIT I went to UNLV $CRCL The hate you have going to eat you up at the cellular level ask $AAPL CEO
0 · Reply
javarich
javarich Jul. 2 at 2:54 PM
$SLS I'm in if you care these are the Pharma #lgcyholo $RARE $KAPA look up pipe, team and look into your soul I bought Lambos years ago now I'm a buddist beetchs
0 · Reply
javarich
javarich Jul. 2 at 2:49 PM
$BBAI so glad I CA down to under $4 this is the next $PLTR kinda sorta. Best Pharma plays on the plant $RARE $KAPA
2 · Reply
javarich
javarich Jul. 2 at 2:47 PM
$RARE $KAPA I reallt should be charging for this but I love when others win too. Be a early bird not late
0 · Reply
CrispDry
CrispDry Jul. 2 at 3:15 AM
$RARE when’s the data coming :/
1 · Reply
javarich
javarich Jul. 1 at 4:27 PM
$RARE tired of the chick spitting in her coffee gtfo is your not in. Analysts azzwipe. 3x mark it, post it, pin it to your cinder in basement.
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 4:27 PM
$RARE secures FDA Breakthrough Therapy status for GTX-102! This designation could accelerate the development and review of treatment for Angelman syndrome, supported by promising early clinical data showing sustained improvements in patients. With shares down 13.2% YTD and limited existing treatments, this could be a pivotal moment for Ultragenyx Pharmaceuticals. Discover the full story here 👉 https://www.zacks.com/commentary/2557986/rares-gtx-102-gets-fdas-breakthrough-status-for-angelman-syndrome?cid=sm-stocktwits-2-2557986-body-455&ADID=SYND_STOCKTWITS_TWEET_2_2557986_BODY_455
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 3:23 PM
$RARE just landed a major win — Breakthrough status from the FDA GTX-102 showed sustained progress in Angelman syndrome patients, earning the coveted designation. See why this could be a game-changer for the pipeline 👉 https://www.zacks.com/stock/news/2557986/rares-gtx-102-gets-fdas-breakthrough-status-for-angelman-syndrome?cid=sm-stocktwits-2-2557986-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2557986_TEASER
0 · Reply
TwoToesTrading
TwoToesTrading Jun. 27 at 7:35 PM
$DOW $PTON $PYPL $RARE $MCHP more delayed flow
0 · Reply
FelixH86
FelixH86 Jun. 27 at 2:45 PM
0 · Reply
DonCorleone77
DonCorleone77 Jun. 27 at 12:09 PM
$RARE Ultragenyx receives Breakthrough Therapy Designation for GTX-102 Ultragenyx Pharmaceutical announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for GTX-102 as a treatment for Angelman syndrome. "FDA Breakthrough Therapy Designation underscores both the urgent need for an effective treatment for patients and families affected by Angelman syndrome and the clinically meaningful results demonstrated to date with GTX-102," said Eric Crombez, M.D., chief medical officer at Ultragenyx. "Based on the strength of the Phase 2 data and with strong support and interest from the Angelman syndrome community, our Phase 3 Aspire study is rapidly enrolling across our global sites. We look forward to advancing GTX-102 through the development process as rapidly as possible to bring this potential treatment to patients."
1 · Reply
onlyGreenPlz
onlyGreenPlz Jun. 25 at 3:53 AM
$RARE Ascending triangle pattern forming? Thoughts?
0 · Reply
Densa
Densa Jun. 24 at 7:19 PM
$RARE What are we exactly w8 for here? I checked the FDA page, RARE Pipline but couldnt find anything... when is the next big decission expected? Thx all!
3 · Reply
CrispDry
CrispDry Jun. 23 at 4:22 PM
$MREO why are they both tanking? $RARE
1 · Reply
CrispDry
CrispDry Jun. 23 at 4:19 PM
$RARE what the heck man
0 · Reply
Quantumup
Quantumup Jun. 23 at 3:19 PM
TD Cowen Notes $RARE $EXLS $KVYO $PLTK GXO as its 2025 Best SMID-cap Ideas. Re: $RARE [ $MREO ] TD Cowen said, "Shares are undervalued given steady commercial growth, promising pipeline + multiple key data readouts." TD Cowen went on to say:
0 · Reply
Quantumup
Quantumup Jun. 23 at 3:13 PM
BofA, on June 10, from its Deep dive into $RARE's OI Interim Analysis said, "If phase 3 is successful, KOLs envision broad usage" - says it sees high likelihood 2nd interim hits given supportive long-term ph 2 data. $MREO BofA additionally said, "Long-term ph 2 data showed pts with 14+ mos follow-up saw their AFR reduced 67% from baseline. At 12-mos, patients saw a 22% mean increase in lumbar spine BMD (6-mos: 14%). If the ph 3 replicates these results, our KOLs indicate that they would offer setrusumab to nearly all of their Ol patients including patients on bisphosphonates."
0 · Reply
clemsoncrew
clemsoncrew Jun. 20 at 4:43 PM
$RARE PT of 64 today https://www.marketbeat.com/ratings/
0 · Reply
CrispDry
CrispDry Jun. 18 at 7:26 PM
$RARE all I got is 3000 shares at $37 level. Let’s get back to ATH. $MREO
1 · Reply